PYC Therapeutics

PYC Therapeutics is a clinical-stage biotech company that targets the underlying drivers of genetic diseases. It combines RNA therapeutics with a proprietary therapeutic delivery platform of cell-penetrating peptides (CPPs) to achieve greater intracellular RNA potency. The company is developing a pipeline of novel therapies in clinical and pre-clinical stage programs focused on diseases of the eye, the central nervous system and the kidney. Its strategy focuses on monogenic and haploinsufficient diseases. PYC Therapeutics is listed on the ASX.

PYC Therapeutics is a clinical-stage biotech company that targets the underlying drivers of genetic diseases. It combines scientific rigour, clinical insights and a proprietary drug delivery platform to create therapies for genetic diseases with limited or no treatment options. The company's RNA delivery platform technology uses cell-penetrating peptides (CPPs) to overcome the challenge of crossing the cell membrane, aiming for safer and more effective treatment of the underlying cause of inherited diseases. PYC Therapeutics is developing a pipeline of novel therapies in clinical and pre-clinical stage programs focused on diseases of the eye, the central nervous system and the kidney. Its strategy focuses on monogenic diseases and haploinsufficient disease targets. The company is listed on the ASX.

Clinical-stage biotech targeting the underlying drivers of genetic diseases with RNA therapeutics and a proprietary delivery platform.

1. 1Home - PYC Therapeuticspyctx.com
2. 2About us - PYC Therapeuticspyctx.com
3. 3Who we are - PYC Therapeuticspyctx.com
4. 4PYC Therapeutics Appoints U.S. Biopharma Executive Jason Haddock to its Board of Directorsbiospace.com
5. 5PYC Therapeutics Appoints U.S. Biopharma Executive Jason Haddock to its Board of Directorsprnewswire.com
6. 6PYC Therapeutics Appoints U.S. Biotech Veteran Michael Rosenblatt, MD, to its Board of Directorsprnewswire.com